Compare HYPR & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | CELU |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.9M | 34.5M |
| IPO Year | 2021 | N/A |
| Metric | HYPR | CELU |
|---|---|---|
| Price | $1.16 | $1.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.28 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 283.6K | 28.0K |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,890,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $34.43 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.84 | N/A |
| 52 Week Low | $0.53 | $1.01 |
| 52 Week High | $2.22 | $4.35 |
| Indicator | HYPR | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 50.50 |
| Support Level | $1.04 | $1.21 |
| Resistance Level | $1.19 | $1.33 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 70.73 | 48.10 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.